TSXV:ADK

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Market Cap

CA$37.6m

Last Updated

2021/06/23 23:31 UTC

Data Sources

Company Financials +

Executive Summary

DIAGNOS Inc. provides software-based interpretation services primarily in Canada, the United States, Colombia, the United Arab Emirates, Bangladesh, Saudi Arabia, and Costa Rica. More Details


Snowflake Analysis

Adequate balance sheet with limited growth.

Share Price & News

How has DIAGNOS's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ADK is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: ADK's weekly volatility (9%) has been stable over the past year.


Market Performance


7 Day Return

3.7%

ADK

-4.4%

CA Healthcare Services

-0.9%

CA Market


1 Year Return

250.0%

ADK

53.3%

CA Healthcare Services

36.1%

CA Market

Return vs Industry: ADK exceeded the Canadian Healthcare Services industry which returned 54% over the past year.

Return vs Market: ADK exceeded the Canadian Market which returned 34.1% over the past year.


Shareholder returns

ADKIndustryMarket
7 Day3.7%-4.4%-0.9%
30 Day-3.4%-10.4%1.9%
90 Day5.7%-20.9%6.2%
1 Year250.0%250.0%53.3%53.3%40.5%36.1%
3 Year-13.8%-13.8%-47.9%-47.9%31.7%19.0%
5 Year24.4%24.4%-30.9%-30.9%59.5%35.6%

Long-Term Price Volatility Vs. Market

How volatile is DIAGNOS's share price compared to the market and industry in the last 5 years?


Simply Wall St News

1 month ago | Simply Wall St

DIAGNOS Inc.'s (CVE:ADK) Profit Outlook

8 months ago | Simply Wall St

How Is DIAGNOS' (CVE:ADK) CEO Compensated?

Valuation

Is DIAGNOS undervalued compared to its fair value and its price relative to the market?

33.29x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ADK's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ADK's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ADK is unprofitable, so we can't compare its PE Ratio to the North American Healthcare Services industry average.

PE vs Market: ADK is unprofitable, so we can't compare its PE Ratio to the Canadian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ADK's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ADK is overvalued based on its PB Ratio (33.3x) compared to the CA Healthcare Services industry average (4x).


Future Growth

How is DIAGNOS forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

123.0%

Forecasted annual revenue growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if ADK's forecast earnings growth is above the savings rate (1.5%).

Earnings vs Market: Insufficient data to determine if ADK's earnings are forecast to grow faster than the Canadian market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: ADK's revenue (123% per year) is forecast to grow faster than the Canadian market (5.6% per year).

High Growth Revenue: ADK's revenue (123% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ADK's Return on Equity is forecast to be high in 3 years time


Past Performance

How has DIAGNOS performed over the past 5 years?

2.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ADK is currently unprofitable.

Growing Profit Margin: ADK is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ADK is unprofitable, but has reduced losses over the past 5 years at a rate of 2% per year.

Accelerating Growth: Unable to compare ADK's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ADK is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (26.9%).


Return on Equity

High ROE: ADK has a negative Return on Equity (-181.19%), as it is currently unprofitable.


Financial Health

How is DIAGNOS's financial position?


Financial Position Analysis

Short Term Liabilities: ADK's short term assets (CA$1.6M) exceed its short term liabilities (CA$550.1K).

Long Term Liabilities: ADK's short term assets (CA$1.6M) exceed its long term liabilities (CA$268.1K).


Debt to Equity History and Analysis

Debt Level: ADK's debt to equity ratio (14.5%) is considered satisfactory.

Reducing Debt: ADK had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ADK has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: ADK has less than a year of cash runway if free cash flow continues to grow at historical rates of 1.9% each year.


Dividend

What is DIAGNOS current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ADK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ADK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ADK's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ADK's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ADK's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.2yrs

Average board tenure


CEO

Andre Larente

17yrs

Tenure

CA$297,213

Compensation

Mr. Andre Larente has been the Chief Executive Officer and President of Diagnos Inc. since June 22, 2004. Mr. Larente served as an Independent Director at Windfall Geotek Inc. (Formerly, Albert Mining Inc....


CEO Compensation Analysis

Compensation vs Market: Andre's total compensation ($USD241.79K) is above average for companies of similar size in the Canadian market ($USD158.83K).

Compensation vs Earnings: Andre's compensation has increased whilst the company is unprofitable.


Board Members

Experienced Board: ADK's board of directors are considered experienced (3.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: ADK insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.3%.


Top Shareholders

Company Information

DIAGNOS Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: DIAGNOS Inc.
  • Ticker: ADK
  • Exchange: TSXV
  • Founded: 1998
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: CA$37.562m
  • Shares outstanding: 68.29m
  • Website: https://www.diagnos.ca

Location

  • DIAGNOS Inc.
  • 7005 Taschereau Boulevard
  • Suite 265
  • Brossard
  • Quebec
  • J4Z 1A7
  • Canada

Listings


Biography

DIAGNOS Inc. provides software-based interpretation services primarily in Canada, the United States, Colombia, the United Arab Emirates, Bangladesh, Saudi Arabia, and Costa Rica. The company offers healthc...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/06/23 23:31
End of Day Share Price2021/06/23 00:00
Earnings2021/03/31
Annual Earnings2021/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.